Roger Franklin is partner at Hadean Ventures, leading the firm’s Stockholm office and sitting as a member of the investment committee. Moving to Hadean in 2018, he has more than 15 years experience focused on the life science industry across investment banking, consulting and venture capital. He focuses on investments in the biotech/therapeutics space, currently acting as board member or observer at seven of Hadean’s portfolio companies in this segment including Emergence Therapeutics, Pipeline Therapeutics, Step Pharma, Targed Biopharmaceuticals, Abliva and Gesynta Pharma. His academic background is in biochemistry where he studied at Oxford University, followed by a PhD in the oncology space from Cambridge University in the UK.